论文部分内容阅读
目的与方法： 观察拓扑替康 (topotecan)对经治晚期卵巢癌患者的疗效和毒性。 67例晚期上皮性卵巢癌患者，年龄 33～ 71岁， 66例曾经手术切除，全部接受过化疗，其中 68.6％患者至少接受过 2种以上方案化疗， 94.0％为含铂类药物治疗失败，采用单药 topotecan 1.25 mg/m2静脉滴注 ,连续 5天，每 21天重复疗程， 85.1％患者用药 2疗程以上。结果： 61例可评价疗效的患者中， CR 6例， PR 7例，总有效率 21.3％。按 ITT分析 67例有效率为 20.9％。中位缓解时间 7.0个月。主要不良反应为血液学毒性， 64.2％患者发生Ⅲ～Ⅳ度白细胞减少， 43.3％患者发生Ⅲ～Ⅳ度血小板减少，中位持续时间 9～ 10天。非血液毒性轻微。结论： Topotecan系晚期卵巢癌经 DDP等药物治疗失败后的有效治疗药物，应在对肿瘤化疗有经验的专科医师监测下使用。
Objective and Methods: To observe the curative effect and toxicity of topotecan on advanced ovarian cancer patients. 67 cases of advanced epithelial ovarian cancer patients, aged 33 to 71 years old, 66 patients had surgery, all received chemotherapy, of which 68.6% received at least two chemotherapy regimens, 94.0% of platinum-containing drugs failed to treat, Monotherapy topotecan 1.25 mg / m2 intravenous infusion for 5 days, repeated treatment every 21 days, 85.1% of patients treated with more than 2 courses. Results: Of the 61 evaluable patients, 6 were CR and 7 were PR, with a total effective rate of 21.3%. According to ITT analysis of 67 cases of 20.9% efficiency. The median response time was 7.0 months. The main adverse reactions were hematological toxicity, with grade Ⅲ ~ Ⅳ leucopenia occurring in 64.2% of patients and grade Ⅲ ~ Ⅳ thrombocytopenia in 43.3% of patients with median duration of 9 to 10 days. Non-hematologic toxicity is mild. CONCLUSIONS: Topotecan is an effective therapeutic drug for failure of advanced ovarian cancer after DDP and other drugs. It should be used under the supervision of experienced specialists in cancer chemotherapy.